Navigation Links
Results From IMPROVE Study Show Therapeutic Effect of New Formulation of Rebif(R) at 16 Weeks in Patients With Multiple Sclerosis
Date:9/21/2008

ts treated with the new formulation of Rebif(R) had zero combined unique active brain lesions at week 16, compared to only 16.7% in the placebo group.

Results for the secondary and tertiary endpoints of the IMPROVE study will be available at the end of the 40-week treatment period.

The safety profile of the new formulation of Rebif(R) reported in this study is consistent with the known safety profile of Rebif(R). No unexpected safety concerns were identified in this study.

The new formulation of Rebif(R) was approved in the European Union in August 2007 and in Canada in September 2007. It is now marketed in all EU countries and in Canada. The new formulation of Rebif(R) is not available in the United States.

About Rebif(R)

Rebif(R) (interferon beta-1a) is a disease-modifying drug used to treat relapsing forms of multiple sclerosis (MS) and is similar to the interferon beta protein produced by the human body. The efficacy of Rebif(R) in chronic progressive MS has not been established. Interferons are thought to help modulate the body's immune system and reduce inflammation. The exact mechanism is unknown.

Rebif(R), which was approved in Europe in 1998 and in the US in 2002, is registered in more than 80 countries worldwide. Rebif(R) has been proven to delay the progression of disability, reduce the frequency of relapses and reduce MRI lesion activity and area.* Rebif(R) is available in a 22 micrograms and 44 micrograms ready-to-use pre-filled syringe and a titration pack (8.8 micrograms).

Rebif(R) should be used with caution in patients with a history of depression, liver disease and seizures. Most commonly reported side effects are flu-like symptoms, injection site disorders, elevation of liver enzymes and blood cell abnormalities. Patients, especially those with depression, seizure disorders, or liver problems, should discuss treatment with Rebif(R) with their doctors. For more information about Rebif(R), please visi
'/>"/>

SOURCE Merck Serono
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine news :

1. Haemacure Reports Third Quarter 2007 Results
2. Brooke Franchise Corporation Announces Selected July Results
3. AKELA Pharma Inc. announces positive results for the extension part of its Phase IIb Fentanyl TAIFUN(R) trial
4. Somanetics Corporation to Release Third Quarter 2007 Financial Results and Host Conference Call September 19
5. The New England Journal of Medicine Publishes EURIDIS/ADONIS Study Results Showing Dronedarone Maintained Sinus Rhythm in Patients With Atrial Fibrillation or Flutter With no Observed Pro-Arrhythmia
6. NBTY Announces Preliminary Unaudited Net Sales Results For August 2007
7. Martek Announces Third Quarter 2007 Financial Results
8. MDS Reports Third Quarter 2007 Results
9. Authentidate Holding Corp. to Report Fourth Quarter and Fiscal 2007 Year End Results on Thursday, September 13, 2007
10. Robbins & Myers to Release Fourth Quarter and 2007 Fiscal Year Results on Monday, October 15, 2007
11. NMHC Reports Fourth Quarter and Fiscal Year 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/1/2015)... , ... August 01, 2015 , ... On Tuesday, July ... , who are thought to have been behind the attack on Anthem Inc. which ... were zero day exploits, watering hole attacks and spear phishing campaigns. , ...
(Date:8/1/2015)... ... ... March 19, 2015 Phil Valentine – the Executive Director of Connecticut Community for Addiction Recovery ... off Springer Mountain and heading north. Since that day, Phil has hiked over 1400 miles ... by friends and family. He visited CCAR and left an inspirational message to his ...
(Date:7/31/2015)... (PRWEB) , ... August 01, 2015 , ... The Honor ... Global Advisory Panel on the Future of Nursing (GAPFON) 20-21 July 2015 in San ... to participate in this meeting. , Dr. Silvia Cassiani, Advisor, Nursing and Allied Health ...
(Date:7/31/2015)... ... July 31, 2015 , ... Recently ... know in predictive health analytics , Jvion continues to disrupt the predictive ... predictive software that targets patient and population level illness to drive prevention and ...
(Date:7/31/2015)... ... ... There’s no better way to enjoy the summer weather than by being ... meal, making July the most appropriate to be National Hot Dog Month. King Kullen ... the next cookout different than the ones in the past. Celebrate National Hot Dog ...
Breaking Medicine News(10 mins):Health News:Frenemy at the Gates - Hackers Excel at Leveraging Trust 2Health News:Frenemy at the Gates - Hackers Excel at Leveraging Trust 3Health News:Frenemy at the Gates - Hackers Excel at Leveraging Trust 4Health News:Connecticut Executive Hikes Appalachian Trail to Raise Awareness About Recovery. 2Health News:Key Latin American Nurse Leaders Identify Regional Issues During Global Advisory Panel on the Future of Nursing Meeting 2Health News:Key Latin American Nurse Leaders Identify Regional Issues During Global Advisory Panel on the Future of Nursing Meeting 3Health News:Key Latin American Nurse Leaders Identify Regional Issues During Global Advisory Panel on the Future of Nursing Meeting 4Health News:Jvion Showcased as Leader in the Predictive Analytic Market 2Health News:King Kullen Honors National Hot Dog and Blueberry Month 2Health News:King Kullen Honors National Hot Dog and Blueberry Month 3
... plays a surprising role reducing the level of infection caused ... cancer patients and others with weakened immune systems. The ... fungal evaders by enhancing the body,s ability to chew them ... where it would continue to provoke an onslaught of harmful ...
... August 19, 2010The first successful report of using cell-depleted lung ... from embryonic stem cells is presented in a breakthrough article ... published by Mary Ann Liebert, Inc. ( www.liebertpub.com ). The ... Embryonic stem cells (ESCs) have the potential to mature into ...
... doctoral student Lisa Carter-Harris has received the Johnson & ... Colleges of Nursing Minority Nursing Faculty Scholarship for the ... to graduate nursing students from minority backgrounds who agree ... , The AACN will hold $1,500 to cover expenses ...
... A recent study by researchers at Penn State College of ... lupus erythematosus (SLE) patients at the time of hospital admission ... women were youngest to both be admitted with CVD and ... the study appear in the September issue of Arthritis ...
... Reporter , WEDNESDAY, Aug. 18 (HealthDay News) -- Fibromyalgia sufferers ... tai chi, new research finds. Researchers divided 66 people ... of tai chi twice a week for 12 weeks; the ... stretching. At the end of 12 weeks, the ...
... A team of University of Michigan scientists has found ... roundworms. Scientists who study aging have long known that significantly ... is to find less drastic ways to achieve the same ... evidence that scientists may succeed at finding targets for drugs ...
Cached Medicine News:Health News:Old drug holds promise against opportunistic lung bug 2Health News:Old drug holds promise against opportunistic lung bug 3Health News:Old drug holds promise against opportunistic lung bug 4Health News:Natural lung material is promising scaffold for engineering lung tissue using embryonic stem cells 2Health News:UofL student wins national minority nursing scholarship 2Health News:Black women with SLE develop cardiovascular disease at early age 2Health News:Black women with SLE develop cardiovascular disease at early age 3Health News:Tai Chi May Help Ease Fibromyalgia 2Health News:Tai Chi May Help Ease Fibromyalgia 3Health News:Discovery may aid search for anti-aging drugs 2Health News:Discovery may aid search for anti-aging drugs 3
(Date:7/30/2015)... SAN DIEGO, July 30, 2015  ResMed Inc. (NYSE: ... ended June 30, 2015.  Revenue for the quarter was ... quarter ended June 30, 2014 (a 17 percent increase ... million, consistent with the quarter ended June 30, 2014. ... consistent with the quarter ended June 30, 2014.  ...
(Date:7/30/2015)... , July 30, 2015  Today we bring you a special edition of ... to remind you about some of our Medicare resources and continue highlighting the success ... Check out our latest infographics and videos here: ... ... ...
(Date:7/30/2015)... 30, 2015  Amgen (NASDAQ: AMGN ) ... of 2015. Key results include: , Total ... of 2014 to $5,370 million, with 6 percent ... (etanercept), Prolia ® (denosumab), Sensipar ® ... ® (denosumab). Unfavorable changes in foreign exchange ...
Breaking Medicine Technology:ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 2ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 3ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 4ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 5ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 6ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 7ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 8ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 9ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 10ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 11ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 12ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 13ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 14ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 15ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 16Happy 50th Anniversary Medicare! 2Happy 50th Anniversary Medicare! 3Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 2Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 3Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 4Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 5Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 6Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 7Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 8Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 9Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 10Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 11Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 12Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 13Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 14Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 15Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 16Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 17Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 18Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 19
... tells her story but sometimes showing a few less chapters ... quest continues for new ways to keep skin looking its ... survey commissioned by Ulthera ® (the manufacturer of the ... a non-invasive lift indication), 83 percent of women admitted they ...
... Boston Scientific Corporation (NYSE: BSX ) today ... the 60th Annual Scientific Session of the American College ... "Twelve-month results from the PLATINUM Workhorse clinical ... Element™ Everolimus-Eluting Platinum Chromium (PtCr) Stent as compared to ...
Cached Medicine Technology:What Would Women Give Up for a More Youthful Face? 2What Would Women Give Up for a More Youthful Face? 3Boston Scientific Announces Its ACC 2011 Schedule 2Boston Scientific Announces Its ACC 2011 Schedule 3Boston Scientific Announces Its ACC 2011 Schedule 4Boston Scientific Announces Its ACC 2011 Schedule 5Boston Scientific Announces Its ACC 2011 Schedule 6
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: